Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (not Alteryx Therapeutics Ltd) covers the month of November 2005. The document reports the results of the company's Annual General Meeting (AGM) held on November 30, 2005, in Melbourne, Australia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Voting Results
All resolutions presented at the AGM were carried on a show of hands. The specific voting tallies for the resolutions were as follows:
- Director Elections: Re-election of Mr. Brian Meltzer and Dr. George Mihaly, and election of Mr. Peter Marks, each received 18,226,609 votes in favor, 26,013 against, and 21,000 abstentions.
- Share Plan Pool Increase: Received 18,069,389 votes in favor, 186,933 against, and 17,300 abstentions.
- Previous Issue of Securities to Consultant: Received 18,119,809 votes in favor, 136,513 against, and 17,300 abstentions.
- Option Grants: Grants to Prof. Colin Masters and Mr. Peter Marks each received 18,047,402 and 18,047,389 votes in favor respectively, with approximately 211,200 votes against and 15,000 abstentions.
- Remuneration Report: The non-binding adoption received 18,129,902 votes in favor, 128,720 against, and 15,000 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely as a record of the AGM proceedings.
Investor Verification Checklist
- Verify the implementation of the approved increase to the Share Plan Pool.
- Confirm the issuance of unquoted options to Prof. Colin Masters and Mr. Peter Marks as approved.
- Review the details of the previous issue of securities to the consultant approved by shareholders.
- Check subsequent filings for the company's financial results, as this 6-K contains no financial data.